Login to Your Account

ASCO Roundup

Thursday, June 7, 2012
• Hutchison MediPharma Ltd., of London, reported Phase I data showing sulfatinib (HMPL-012), a small-molecule inhibitor of vascular endothelial growth factor (VEGF) and fibroblast growth factor receptors, was well tolerated at doses up to 300 mg per day or 150 mg twice daily and demonstrated preliminary antitumor activity in multiple cancer types, including liver cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription